NEW YORK, August 19, 2026, 15:22 EDT
Merck & Co. NYSE:MRK shares jumped 13.3% to $153.12 on Wednesday. The move followed positive Phase 3 results for a personalized melanoma vaccine developed with Moderna NASDAQ:MRNA. Merck touched a record as U.S. markets remained open.
The rally added roughly $44.4 billion to Merck’s implied market value. That calculation uses the intraday price change and about 2.47 billion shares outstanding. It dwarfs current estimates for the melanoma opportunity alone.
| Merck market snapshot | August 19, 15:22 EDT | Method |
|---|---|---|
| Share price | $153.12 | Intraday |
| Previous close | $135.17 | Official prior close |
| Change | +13.28% | Intraday |
| Implied market value | $378.2 billion | Price × 2.47 billion shares |
| Implied one-day value gain | $44.4 billion | Price change × share count |
The pivotal study enrolled 1,137 patients with high-risk melanoma after surgery. Intismeran autogene plus Keytruda met goals for delaying recurrence and distant spread versus Keytruda alone. The companies reported no new safety signal. Full results remain undisclosed.
Moderna President Stephen Hoge called the improvement “clinically significant” and “statistically significant.” The companies are discussing the data with regulators. A launch could come in 2027, though pricing has not been set. Reuters
| Clinical evidence | Phase 3 update | Earlier Phase 2b evidence |
|---|---|---|
| Population | 1,137 patients, stages IIB-IV | 157 patients, stages III-IV |
| Recurrence endpoint | Met; magnitude pending | 49% lower recurrence-or-death risk at five years |
| Distant spread endpoint | Met; magnitude pending | 59% lower distant-metastasis-or-death risk |
| Overall survival | Not yet disclosed | Encouraging trend; exploratory |
| Safety | No new signal reported | Long-term follow-up available |
The valuation gap is the investor signal. Barclays forecasts about $3 billion of annual melanoma sales by 2035. Other published estimates place the melanoma program near $2.5 billion in value. Wednesday’s Merck gain was about 18 times that figure.
That suggests investors priced more than a melanoma launch. Merck and Moderna are testing the platform across several tumors. Success elsewhere could extend Keytruda’s commercial life and soften its coming patent exposure. The trial therefore matters as a platform readout.
| Valuation yardstick | Estimate | Merck’s $44.4bn gain versus yardstick |
|---|---|---|
| Melanoma program value | About $2.5 billion | 17.7× |
| 2035 melanoma annual sales | About $3.0 billion | 14.8× |
| Merck implied value added Wednesday | About $44.4 billion | 1.0× |
Keytruda remains the center of Merck’s earnings base. The franchise generated $8.37 billion in second-quarter sales, including Keytruda Qlex. That was 50.4% of Merck’s $16.61 billion total. The vaccine could protect that base by creating new combinations.
| Merck operating context | Q2 2026 | Year-over-year |
|---|---|---|
| Total sales | $16.61 billion | +5% |
| Keytruda franchise sales | $8.37 billion | +5% |
| Keytruda share of total sales | 50.4% | Calculated |
| 2026 sales guidance | $66.3-$67.3 billion | Company range |
Wall Street had not priced Wednesday’s move. The average analyst target was $136.04 before the rally, 11.2% below the intraday price. Even the $155 high target left only 1.2% upside. Estimate revisions now matter more than the existing consensus.
| Analyst recommendations | Count | Target or implication |
|---|---|---|
| Strong Buy | 15 | Consensus: Buy |
| Buy | 4 | |
| Hold | 8 | |
| Sell | 1 | |
| Average target | $136.04 | -11.2% versus $153.12 |
| Median target | $140.50 | -8.2% |
| High target | $155.00 | +1.2% |
Moderna’s sharper move reinforces the platform reading. Its shares more than doubled, with trading volume about 15 times the 50-day average. Moderna and Merck split profits from the collaboration equally.
Risks: The companies have not released hazard ratios, survival data or detailed safety results. Regulators must assess individualized manufacturing, turnaround times and consistency. Pricing also remains open. A weaker full presentation could unwind part of Wednesday’s premium.
The next test is quantitative. Investors need the full Phase 3 curves and regulatory timetable. Until then, Merck’s new record price assumes the vaccine can become more than a melanoma product.
Related articles: NYSE:MRK
The market priced a platform
NYSE open · Nasdaq real-time price feed
One day outran melanoma-only estimates
Merck's value gain was nearly 18 times one published valuation for the melanoma program.
What the tape is assuming
A melanoma approval is only the first layer. The premium also reflects Keytruda lifecycle extension and shots in other tumors.
- Phase 3 recurrence endpointMet
- Distant-spread endpointMet
- Full efficacy and survival dataPending
- Regulatory path and pricingOpen
Keytruda still carries the quarter
$8.37 billion of Q2 sales came from the Keytruda franchise—50.4% of Merck's $16.61 billion total.
Consensus is suddenly stale
The average target sat 11.2% below the intraday price. Even the high target offered just 1.2% upside.
